 Antineoplastic Agents, Phytogenic
"Antineoplastic Agents, Phytogenic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
| Descriptor ID |
D000972
|
| MeSH Number(s) |
D27.505.954.248.179
|
| Concept/Terms |
Antineoplastic Agents, Phytogenic- Antineoplastic Agents, Phytogenic
- Agents, Phytogenic Antineoplastic
- Phytogenic Antineoplastic Agents
- Antineoplastics, Phytogenic
- Phytogenic Antineoplastics
- Antineoplastics, Botanical
- Botanical Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Phytogenic".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Phytogenic".
This graph shows the total number of publications written about "Antineoplastic Agents, Phytogenic" by people in this website by year, and whether "Antineoplastic Agents, Phytogenic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 | | 1996 | 4 | 1 | 5 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 2 | 3 | | 2002 | 2 | 2 | 4 | | 2003 | 3 | 3 | 6 | | 2004 | 3 | 2 | 5 | | 2005 | 7 | 1 | 8 | | 2006 | 7 | 5 | 12 | | 2007 | 6 | 3 | 9 | | 2008 | 3 | 1 | 4 | | 2009 | 4 | 1 | 5 | | 2010 | 5 | 1 | 6 | | 2011 | 1 | 5 | 6 | | 2012 | 4 | 2 | 6 | | 2013 | 4 | 2 | 6 | | 2014 | 4 | 1 | 5 | | 2015 | 1 | 0 | 1 | | 2016 | 4 | 3 | 7 | | 2017 | 4 | 1 | 5 | | 2018 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents, Phytogenic" by people in Profiles.
-
Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, Goodman KA, Esfahani A. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer. 2018 Oct 05; 18(1):958.
-
Dhar D, Deep G, Kumar S, Wempe MF, Raina K, Agarwal C, Agarwal R. Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog. 2018 09; 57(9):1166-1180.
-
Manley PE, Trippett T, Smith AA, Macy ME, Leary SES, Boklan J, Cohen KJ, Goldman S, Kilburn LB, Dhall G, Devin J, Herzog CE, Partap S, Fauchet F, Badreddine E, Bernard JP, Chi SN. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatr Blood Cancer. 2018 09; 65(9):e27217.
-
Wainberg ZA, Alsina M, Soares HP, Braña I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol. 2017 Dec; 12(6):775-785.
-
Benasutti H, Wang G, Vu VP, Scheinman R, Groman E, Saba L, Simberg D. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population. Bioconjug Chem. 2017 11 15; 28(11):2747-2755.
-
Sinha N, Panda PK, Naik PP, Das DN, Mukhopadhyay S, Maiti TK, Shanmugam MK, Chinnathambi A, Zayed ME, Alharbi SA, Sethi G, Agarwal R, Bhutia SK. Abrus agglutinin promotes irreparable DNA damage by triggering ROS generation followed by ATM-p73 mediated apoptosis in oral squamous cell carcinoma. Mol Carcinog. 2017 Nov; 56(11):2400-2413.
-
Atigh MK, Turner E, Christians U, Yazdani SK. The use of an occlusion perfusion catheter to deliver paclitaxel to the arterial wall. Cardiovasc Ther. 2017 Aug; 35(4).
-
Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 01; 123(19):3843-3854.
-
Madden JR, Evans A, Hemenway M, Stark E, Kissell E, Polito A, Batson D, Stark M, Dhall G, Garvin JH, Foreman NK, Vibhakar R. Vincristine and Vinblastine: Is checking bilirubin mandatory in children with Brain Tumors? Pediatr Blood Cancer. 2017 06; 64(6).
-
Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A, Clement PM. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2016 Dec 15; 122(24):3803-3811.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|